It showed that epithelial KRAS-dependent stromal IL33 expression affected the pancreatic TME, as the loss of this cytokine increased CD8+ T cell infiltration and activation and, ultimately, reduced tumor growth, making IL33 another therapeutic target option [167]. This evidence concerns the gene KRAS and neoplasm.